Ann: Appendix 4E and Financial Report FY19, page-36

I unfortunately agree with you, exec rem has NOT been aligned with performance.

Meanwhile I notice there's no mention of "end of first quarter 2020" for Akida release on chip - just "it is expected that the Group will further develop the Akida Neuromorphic System-on-Chip (NSoC)". But they covered their behinds by listing every single business risk they could think of (including delays and funding).

Their forecasting and communication is the worst I've personally seen. Too many broken promises and wildly inaccurate forecasts (especially regarding revenue and development timelines).

*sigh*

What can a measly retail shareholder do?